Is it time to tailor treatment on the basis of minimal residual disease in multiple myeloma?

Lancet Haematol. 2021 Dec;8(12):e876-e877. doi: 10.1016/S2352-3026(21)00341-0.
No abstract available

MeSH terms

  • Humans
  • Multiple Myeloma* / drug therapy
  • Neoplasm, Residual

Associated data

  • ClinicalTrials.gov/NCT03104842
  • ClinicalTrials.gov/NCT03188172
  • EudraCT/2019-001258-25
  • EudraCT/2010-019173-16